Zimmer Biomet Holdings (ZBH) Cash & Equivalents (2009 - 2026)

Zimmer Biomet Holdings has reported Cash & Equivalents for 18 years, with the latest figure at $424.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 69.36% year-over-year to $424.2 million; the trailing twelve-month figure through Mar 2026 stood at $424.2 million (down 69.36% YoY), and the FY2025 full-year result was $591.9 million, up 12.64% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $424.2 million, down from $591.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $1.4 billion in Q1 2025, with the low at $292.1 million in Q3 2023.
• Average Cash & Equivalents over 5 years is $544.6 million, with a median of $424.2 million recorded in 2026.
• Year-over-year, Cash & Equivalents surged 252.29% in 2025 and sank 69.36% in 2026.
• Tracing ZBH's Cash & Equivalents over 5 years: stood at $375.7 million in 2022, then grew by 10.67% to $415.8 million in 2023, then gained by 26.38% to $525.5 million in 2024, then grew by 12.64% to $591.9 million in 2025, then slipped by 28.33% to $424.2 million in 2026.
• The last three Cash & Equivalents figures came in at $424.2 million (Q1 2026), $591.9 million (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.

Peer Comparison